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Protocol
AbstrACt
Introduction Attention-deficit hyperactivity disorder 
(ADHD) is characterised by symptoms of inattention, 
hyperactivity and impulsivity. To improve outcomes, the 
National Institute for Health and Care Excellence ADHD 
guidelines recommend regular monitoring of symptoms 
when children commence medication. However, research 
suggests that routine monitoring rarely happens, and 
clinicians often rely on subjective information such 
as reports from parents and teachers to ascertain 
improvement. These sources can be unreliable and difficult 
to obtain. The addition of an objective test of attention and 
activity (QbTest) may improve the objectivity, reliability 
and speed of clinical decision-making and so reduce the 
time to identify the optimal medication dose. This study 
aims to assess the feasibility and acceptability of a QbTest 
medication management protocol delivered in routine 
healthcare services for children with ADHD.
Method and analysis This multisite feasibility 
randomised controlled trial (RCT) will recruit 60 young 
people (aged 6–17 years old), diagnosed with ADHD, 
and starting stimulant medication who are seen by Child 
and Adolescent Mental Health Services or Community 
Paediatric services. Participants will be randomised 
into one of two arms. In the experimental arm (QbTest 
protocol), the participant will complete a QbTest at 
baseline (prior to medication initiation), and two follow-up 
QbTests on medication (2–4 weeks and 8–10 weeks later). 
In the control arm, participants will receive treatment as 
usual, with at least two follow-up consultations. Measures 
of parent-, teacher- and clinician-rated symptoms and 
global functioning will be completed at each time point. 
Health economic measures will be completed. Clinicians 
will record treatment decision-making. Acceptability 
and feasibility of the protocol will be assessed alongside 
outcome measure completion rates. Qualitative interviews 
will be conducted.
Ethics and dissemination The findings will be used to 
inform the development of a fully powered RCT. The results 
will be submitted for publication in peer-reviewed journals. 
The study has ethical approval.
trial registration number NCT03368573; Pre-results.
IntroduCtIon  
Attention-deficit hyperactivity disorder 
(ADHD) affects 3%–5% of children and 
young people under 18 years old.1 The core 
symptoms include inattention, impulsivity 
strengths and limitations of this study
 ► The study uses a pragmatic intervention randomised 
controlled trial (RCT) design conducted in routine 
National Health Service settings.
 ► Adding QbTest to routine care for medication man-
agement has not yet been attempted in the UK. In 
line with Medical Research Council guidelines on 
complex interventions, we need to first establish the 
feasibility of the research design.
 ► The protocol was co-created with a multidisciplinary 
team of experts, including healthcare professionals, 
patient and public involvement members, expert 
statisticians and health economists, and academics.
 ► If the protocol is deemed feasible and acceptable, 
a further fully powered RCT would be necessary to 
determine the health and economic impact of add-
ing QbTest to medication management for atten-
tion-deficit hyperactivity disorder.
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and hyperactivity leading to significant impairments 
in academic and social function and increased risk of 
substance misuse, unemployment, criminality and mental 
health problems.2 3 Early treatment is crucial to improve 
symptoms and reduce the burden on the family and 
wider social and healthcare systems.4 With the increasing 
rates of diagnosis of ADHD, spending on ADHD medi-
cation has increased sevenfold between 1998 and 2005,5 
and expenditure on medication treatment costs in the 
UK is now estimated at £78 million per year.5 6 This has 
placed increasing financial burden on health services and 
highlighted the need for more efficient and cost-effective 
services to diagnose and treat the condition. Indeed, 
the National Institute for Health and Care Excellence 
(NICE) guidelines1 emphasise the importance of young 
people with ADHD having access to the best evidence-
based care in order to fulfil their potential and prevent 
poor outcome. However, in practice, delivery and quality 
of care is variable with little consistency in diagnosis or 
management.7 Improving child and adolescent mental 
health services is a current government priority.8 
NICE ADHD guidelines1 recommend frequent moni-
toring of ADHD symptoms in children and young people 
prescribed medication to ensure first, that the best dose 
of medication is reached quickly for each child and 
second, that the effectiveness of this dose is monitored 
regularly, ensuring optimal outcomes are maintained with 
minimal side effects. The US National Institute of Mental 
Health Multimodal Treatment Study of ADHD (MTA)9 
showed that frequent symptom monitoring with careful 
adjustment of the dose significantly improved outcomes 
in ADHD. In this study, the proportion of children that 
experienced a clinically significant reduction in symptoms 
was almost 60% compared with only 25% for those not 
subjected to this careful monitoring procedure.9 While 
treatments for ADHD are highly efficacious in carefully 
managed research settings,1 in standard community care 
careful monitoring is rarely possible and the outcome of 
treatment may be suboptimal. Audit data within the East 
Midlands showed that community care for ADHD falls 
well below the standards for titration and monitoring set 
out in the MTA and NICE guidelines.7 Aside from delays 
in initiating treatment caused by diagnostic uncertainty, 
once on medication, children may not be reviewed suffi-
ciently frequently for clinicians to detect non-response or 
partial response, or to establish the optimal dose for 
each child. Research has demonstrated that families are 
often unhappy with the length of time to attain reach 
an optimal dose of medication (up to 18 months), with 
very few participants reporting titration was achieved in 
the 6-week time frame advocated by NICE.10 These issues 
mean that children may not experience the full benefits 
of medication and this has significant negative effects on 
their academic, social and psychological development. A 
further consequence of suboptimal treatment response 
in routine care is poor medication adherence. In the UK, 
50% of patients have stopped ADHD medication after 18 
months and 80% after 3 years.11
Current methods to judge the effectiveness of medi-
cation rely on the clinician integrating various forms of 
subjective information, information such as clinical rating 
scales completed by parents and teachers, with their own 
observations. However, the information provided by these 
sources can be contradictory, partially completed or not 
returned in a timely manner leading to delays in treat-
ment decisions. Adding more objective, computerised 
tests to clinical care for ADHD is one approach which has 
received increasing clinical and research recognition.12 
The continuous performance test (CPT) is a computer-
ised neuropsychological test that measures the individu-
al’s capacity to sustain attention (vigilance) and inhibit 
inappropriate responses (impulsivity). Several studies 
have noted improvement in CPT scores in children 
with ADHD on stimulant medication13–15 indicating the 
potential utility of these tests to aid medication manage-
ment in clinical practice. However, there is a need for 
further research on CPTs examining the clinical utility 
and cost-effectiveness using randomised controlled trials 
(RCTs).16 Furthermore, a limitation of the CPT is that 
it does not measure the patients’ activity levels, which 
is a core symptom domain of ADHD. A recent system-
atic review16 indicated that a combination of a CPT with 
objective direct measure of bodily activity during the 
test may be particularly useful as a clinical tool. One test 
that combines the CPT with a measure of activity is the 
‘QbTest’ (Qbtech, www. qbtech. com), a commercially 
available measure of ADHD symptoms approved by 
the Food and Drug Administration (FDA) (Reference: 
K133382). The QbTest takes approximately 20 min to 
complete, during which time the child/young person is 
seated in front of a computer and is instructed to press a 
hand-held responder button each time a predesignated 
infrequent target stimulus appears on-screen, and to with-
hold the response to all other stimuli. These features of 
QbTest measure sustained and selective attention (target 
detection over 600 stimulus presentations), and impul-
sivity (withholding the response to a non-target). Simul-
taneously, an infrared camera tracks the movement of a 
marker attached to a headband worn during the test, to 
measure activity. All young people aged 6–17 years can sit 
the QbTest providing they do not have moderate/severe 
learning difficulty. The test provides a summary score 
relevant to each symptom domain (inattention, hyperac-
tivity, impulsivity) with reference to a large age-stratified 
and gender-stratified normative database.17 The QbTest 
should not be used to reach a decision about diagnosis 
or medication without additional clinical information 
but aids decision-making by providing another source of 
information, reducing reliance on questionnaires.
Recent research has investigated the use of the QbTest 
to aid in the clinical assessment of ADHD. QbTest can 
help differentiate ADHD from other conditions18–20 and 
audit data suggests that QbTest can reduce the number 
of appointments needed to confirm a diagnosis of ADHD 
and result in cost savings to health services.21 A recent 
RCT with health economic analysis further investigated 
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whether the QbTest can reduce the number of appoint-
ments needed to make a diagnostic decision on ADHD.22 
Initial qualitative findings from this trial indicate that the 
QbTest is acceptable to children and families and feasible 
to implement in routine clinical settings.23 Furthermore, 
the qualitative interviews revealed that some clinicians 
currently use QbTest to: improve confidence in diagnosis 
before initiating medication; reassure families, young 
people and schools of medication efficacy to improve 
adherence and review medication effects at follow-up 
to aid decisions around dose adjustment.23 These find-
ings highlight the potential clinical utility of the QbTest 
in medication management. In support of this, other 
research has shown that QbTest is sensitive to the effects 
of stimulant medication24 and, in a placebo-controlled 
trial of atomoxetine that performance improvements 
correlate with blinded observer ratings of ADHD symp-
toms.25 It has also shown some utility in identifying partial 
or non-responders after a single dose of methylpheni-
date.26 Another study in adults with ADHD showed that 
the QbTest was more sensitive to medication effects than 
a standardised rating scale.27
Although promising, few of these previous studies 
were conducted in the UK. Moreover, although some 
clinics within the UK, Europe and the USA are using 
QbTest to aid medication management, there is no 
standard approach and most clinics still rely on tradi-
tional approaches of using rating scales and clinical 
judgement. There is a need to formally evaluate the 
role of the QbTest to aid medication management in 
ADHD and assess whether the test should be routinely 
incorporated in healthcare services. In line with the 
Medical Research Council guidance on evaluating 
complex interventions (interventions (ww w.mr c.ac.
uk/ c ompl exi nte rven tion sgui dance), the aim of this 
‘QbTest Utility for Optimising Treatment in ADHD’ 
(QUOTA) study is to assess the feasibility and accept-
ability of a novel QbTest medication management 
protocol in a parallel group, single-blind, feasibility 
RCT with embedded qualitative evaluation. To ascer-
tain the clinical utility of the protocol in standard 
practice, treatment as usual (TAU) was the chosen 
comparator. The findings from this study will be used 
to inform the decision to conduct a fully powered, 
definitive RCT investigating whether QbTest can help 
reduce the time to reach an optimal, effective medica-
tion dose.
MEthods And AnAlysIs
QUOTA trial commenced on 1 April 2017 and consists 
of two stages: stage 1 consisted of a series of three 
expert workshops which were conducted with the aim of 
designing QUOTA research protocol. Stage 2 consists of 
the feasibility RCT.
stage 1: expert workshop summary
The research study measures and medication manage-
ment protocol were designed through a series of three 
expert workshops held from April to July 2017. The 
workshops consisted of up to 21 multidisciplinary 
experts including: 4 patient and public involve-
ment (PPI) members (parents of young people with 
ADHD; including coauthor NB), 1 education expert, 
2 representatives and clinical advisors from Qbtech, 1 
health economics expert, 9 healthcare professionals 
(including consultant psychiatrists, paediatricians 
and nurse specialists incorporating coauthors CLH, 
KSa, JC, KSe), 2 academic team members (MJG and 
CLH) and 2 representatives from National Institute 
for Health Research Health Technology Assessment 
MindTech (JLM and SB), who also bought additional 
PPI expertise.
Through group discussion the expert panel made 
decisions on: the role and frequency of the QbTest in 
the medication protocol, the selection and frequency of 
outcome measures, the design of the health economic 
resource use measures and clinician proforma.
stage 2: feasibility rCt
Trial design
The study is a parallel group, single-blind multicentre 
feasibility RCT, which explores feasibility and accept-
ability of a QbTest medication management protocol, 
using quantitative, qualitative and health economic evalu-
ations. The trial is registered with  ClinicalTrials. gov (www. 
clinicaltrials. gov; NCT03368573) and is at the pre-results 
stage. The study flow is outlined in figure 1. The trial 
consists of two arms.
Experimental arm (QbTest group)
In this arm, participants will receive standard TAU plus 
three QbTests. The participant will complete a QbTest at 
baseline, prior to medication initiation (if a QbTest has 
not already been completed <12 weeks prior to medica-
tion initiation as part of their diagnosis), and again at 
follow-up 1 (2–4 weeks later) and follow-up 2 (8–10 weeks 
later). The clinician will use the QbTest scores to inform 
their clinical decision-making regarding medication deci-
sions (ie, to inform titration, drug choice or treatment 
switch/termination).
Control arm (TAU)
In this arm, participants will receive standard TAU. 
However, to provide some control over the possible 
increased clinical contact in the experimental arm, clini-
cians are requested to make at least two contacts with the 
participant during the 12-week follow-up period. These 
contacts may take place over telephone.
The patients usual care team will be responsible for 
conducting the QbTest in clinic appointments. The 
QbTest will be only be conducted by trained QbTest 
clinicians. Although TAU differs across sites/clini-
cians’/cases, it typically involves clinical interviews 
with the parents/carer/young person to ascertain 
improvement in symptoms, and sometimes collection 
of standardised outcome measures. The TAU care 
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practices will be recorded on a specifically created 
clinician-completed pro forma (see the Measures 
section). There are no prohibited concomitant inter-
ventions. Given this study is assessing the feasibility 
of the protocol no measures will be taken to improve 
protocol adherence.
setting
Child and Adolescent Mental Health Services (CAMHS) 
and Community Paediatric clinics across three different 
National Health Service (NHS) Trusts in England are 
participating in the trial, including Medway NHS Foun-
dation Trust (KSe), United Lincolnshire Hospitals NHS 
Trust (JC), North East London NHS Foundation Trust 
(HV).
recruitment and eligibility
Recruitment is scheduled to start 1 December 2017. 
Patients with a confirmed ADHD diagnosis and 
commencing stimulant medication for ADHD will 
be invited to participate in the research based on the 
following criteria:
Inclusion criteria
 ► age 6–17 years old (at the time of consent)
 ► male or female
 ► referred to CAMHS or Community Paediatric services
 ► diagnosed with ADHD
 ► clinician and family (parent/carer and young person/
child) agreement to commence stimulant medication 
for ADHD symptoms
Figure 1 Participant flow diagram. ADHD, attention-deficit hyperactivity disorder; CAMHS, Child and Adolescent Mental 
Health Services; CGI, Clinical Global Impressions Scale; CHU9D, Child Health Utility; SDQ, Strengths and Difficulties 
Questionnaire; SNAP-IV, Swanson, Nolan and Pelham IV. 
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 ► capable of providing written informed consent (over 
16 years old)
 ► parental consent (under 16 years old).
Exclusion criteria
 ► unable to provide informed consent
 ► severe learning disability (to be assessed by clinical 
judgement)
 ► non-fluent English
 ► not commencing stimulant medication (either not 
started on medication at all or started on a non-stim-
ulant medication).
Eligibility will be determined by the treating clinician 
who has read and approved the protocol. Written infor-
mation about the trial will be provided to families by their 
treating clinical team at the point where a decision to start 
stimulant medication has been agreed. There are four 
types of participant information sheets: one for parents/
caregivers, one for young people aged 16 years and older, 
one for young people aged 12–15 years old and one for 
children aged 6–11 years old. The information sheets 
were developed with our PPI group.
Clinicians will be encouraged to ask patients if they 
have any questions/queries before signing consent and 
will have sufficient knowledge of the research protocol to 
answer anticipated questions. Families may consent into 
the study at the appointment they first receive the infor-
mation sheet, once they have had time to discuss the study 
and ask any questions with the clinician. The PPI group felt 
this would not put undue stress on families and was neces-
sary to avoid any delays in medication initiation for those 
wishing to participate. Clinic invitations will be updated 
on a password-protected database, recording numbers 
invited, numbers declined and reasons for decline. Each 
site will be informed of their monthly recruitment target 
required in order to meet the target sample size.
Measures
Blinded outcome assessors will be fully trained in all 
trial assessments and will be responsible for the delivery, 
monitoring, completion and data entry of all outcome 
measures.
Given this is a feasibility RCT, there is no specified 
primary outcome. The primary outcome for a future 
definitive RCT will be selected through our workshops 
(stage 1) and postintervention interviews (stage 2) as 
being most clinically meaningful and important to our 
workshop experts, and also is shown to be acceptable 
for participants to complete in the feasibility RCT. The 
measures collected during this trial include:
 ► Swanson, Nolan and Pelham version IV (SNAP-IV)28: 
SNAP-IV is a short, 26-item questionnaire designed to 
assess ADHD symptoms. SNAP-IV will be completed 
by parents/carers and teachers at baseline, follow-up 
1 and follow-up 2. A 25% reduction in scores from 
baseline to follow-up 2 was identified in the work-
shops (stage 1) as an appropriate potential primary 
outcome measure.
 ► Strengths and Difficulties Questionnaire (SDQ)29: 
The SDQ is a brief, 25-item behavioural screening 
questionnaire which can be used as part of a clin-
ical assessment for ADHD. The questionnaire also 
contains a brief impact supplement which assesses the 
burden and impact of symptoms.30 The SDQ will be 
completed by parents/carers and teachers at baseline 
and follow-up 2.
 ► Clinical Global Impressions Scale (CGI)31: The CGI is 
a clinician-completed measure designed to measure 
the clinician view of global functioning prior to, and 
after, treatment initiation. The questionnaire consists 
of two items, one measuring symptom severity and 
one measuring change since treatment. The CGI 
will be completed by the clinician at baseline and 
follow-up 2.
 ► Child Health Utility (CHU9D)32: The CHU9D is a 
quality of life measure designed for the economic 
evaluation of interventions for young people. The 
CHU9D will be completed by parents/carers/young 
people at baseline, follow-up 1 and follow-up 2.
 ► QbTest: Q scores for attention, impulsivity and activity 
will be compared between the two groups. The QbTest 
is completed by the young person at baseline (if not 
conducted as part of the diagnostic assessment within 
12 weeks of medication initiation), follow-up 1 and 
follow-up 2.
 ► Side effects scale.33 A side effects scale will be 
completed by parents/carers/young people and 
teachers at follow-up 1 and follow-up 2 to check for 
any differences in side effects between the two treat-
ment groups.
 ► Medication adherence questionnaire: To ascertain 
that participants have been taking medication, they 
will be asked to complete a brief questionnaire created 
specifically for this study which asks how often they 
have taken their medication over the past 4 weeks. 
The questionnaire will be completed by parents/
carers/young people at follow-up 1 and follow-up 2.
 ► Resource Use—Services for Health (RUSH) and 
Resource Use—Services in Education (RUSE): To 
collect relevant health economic information, two-tai-
lored resource use tools will be used to measure the 
use of services used by the family and to ascertain indi-
rect costs (such as time off work). More specifically, 
RUSE measures the use of additionally education 
resources. The measures were based on the Client 
Service Receipt Inventory,34 and refined for use in 
this study by our multidisciplinary group of members 
(including PPI, clinicians and a health economic 
expert (MJ)) in our expert workshops (stage 1). The 
measures will be completed by parents (RUSH) and 
teachers (RUSE) at follow-up 2.
 ► Clinical pro forma: As part of the expert workshops, 
a specifically created pro forma was designed for 
completion by clinicians after each consultation with 
the young person and/or family. The pro forma docu-
ments information about appointment duration, 
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diagnosis and changes to medication/treatment. The 
pro forma can be provided by contacting the corre-
sponding author.
SNAP-IV,35 SDQ,36 CGI,37 CHU9D38 and side effects 
scale33 have established reliability, validity and history 
of use in clinical and research settings. As this is a feasi-
bility study, there are no plans to promote retention and 
follow-up measure completion, but completion rates will 
be recorded to inform the future RCT.
Additionally, a subsample of 10–15 participants 
(parents/carers and/or young people) in the experi-
mental arm will be interviewed about their experiences 
of the trial, including their opinion on randomisation; 
within this subsample, we will include participants who 
did not complete the trial, if possible, acknowledging that 
the views and experiences of non-completers may also 
provide useful insight into acceptability. A subsample of 10 
in the control arm will be interviewed about their experi-
ences of ADHD medication. The subsample will be chosen 
at random from each participating site, using a random 
number generator. All clinicians participating in the feasi-
bility RCT will be interviewed, and asked to comment on 
any local factors that influenced delivery of the protocol 
at their site, providing early insight into factors that might 
influence delivery of the multisite RCT and future imple-
mentation of the protocol into the NHS. All interviews 
will take place after their duration in the RCT has been 
completed to avoid any impact on outcome measures. 
Interviews will be digitally recorded, transcribed and anal-
ysed. The results of these interviews will be used to inform 
any refinement of the protocol to improve its acceptability 
before embarking on the definitive RCT.
Table 1 displays the study measures, the informant and 
the time point of completion. All measures will have a 
1-month window for completion, with the exception of 
the clinic pro forma which must be just after the clinic 
appointment and the QbTest which will be completed 
within the specified time frame. For participants who 
withdraw from the trial, the outcome measures already 
collected will be included in analysis, and no further 
outcome measures will be collected.
sample size and justification
The required sample is 60 participants, 30 per study arm. 
Participants will be families (parents/carers and chil-
dren/young people) whose child/young person is about 
to commence stimulant medication for ADHD. These 
sample sizes are large enough to test the feasibility of the 
research procedures and to establish a mean and SD on 
each outcome measure (Hertzog; 2008). The study has an 
8-month recruitment period, requiring 7.5 participants to 
be recruited into the study each month. Based on find-
ings from the AQUA-Trial (which included the three sites 
used in this trial) this target is achievable. Recruitment 
rates and the final target will be used to inform the deci-
sion to proceed to a definitive RCT.
randomisation and blinding
After obtaining informed consent, participants will be 
randomised on a 1:1 ratio into either the QbTest medi-
cation arm (experimental arm) or TAU (control arm). 
Randomisation will take place via sealed opaque enve-
lopes generated by our study statistician (BG). The sealed 
envelopes will be provided to the clinic sites and opened 
at the point of consent by the clinician.
All participants will undergo the same research 
measures, with the exception of the QbTest, which will 
only be in the experimental arm. Outcome assessors for 
all measures will be blind to which arm the participant is 
in. There are no anticipated events in which participant 
unblinding would be necessary.
data analysis plan
As a feasibility study, data analysis will be mainly 
descriptive, as recommended by Lancaster39 and 
Lancaster et al.40 All measures will be summarised by 
group across follow-up time with mean (SD) for normally 
distributed data, median (IQR) for skewed variable 
and frequency (percentage) for categorical measures. 
Together with site-level intraclass correlation coefficient, 
treatment effects and 95% CI will be derived using multi-
level modelling. Recruitment rate and retention rate will 
also be calculated from the data. This information will 
be used to inform the future definitive RCT design. All 
Table 1 Table of study measures 
Measure (and 
informant) Baseline
Follow-up 1
(2–4 weeks)
Follow-up 2
(8–10 weeks)
SNAP-IV 
(P&T)
x x x
SDQ (P&T) x x
CGI (C) x x
CHU9D 
(P&YP)
x x x
Medication 
adherence 
(P&YP)
x x
Side effects 
(P&YP)
x x
QbTest (YP)* x x x
RUSH (P) x
RUSE (T) x
Pro forma (C)† x x x
Subsample 
for interview 
(P, YP, C)
x
*Experimental arm only. 
†Pro forma completed at every appointment.
C, clinician; CGI, Clinical Global Impression Scale; CHU9D, Child 
Health Utility; P, parent/carer; RUSE, Resource Use—Services 
in Education; RUSH, Resource Use—Services for Health; SDQ, 
Strengths and Difficulties Questionnaire; SNAP-IV, Swanson, Nolan 
and Pelham 4th edition; T, teacher completed; YP, young person.
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statistical analysis will be conducted using STATA  V.15. 
No interim analysis is planned.
To inform the acceptability and feasibility of the study 
design the following indices will be recorded and analysed: 
(1) acceptability of randomisation—record of the number of 
patients who do not participate stating randomisation as 
the reason for non-participation, drop-out rates of rando-
misation, errors in randomisation per site; (2) acceptability 
of study design—record of the number of eligible partici-
pants at each site and the percentage that consent to take 
part in the study, number of withdrawals at each follow-up 
time point; (3) acceptability of outcome measures—record of 
completion rates for outcome measures, percentage of 
data collected online, via telephone or postal completion; 
(4) acceptability/feasibility of the protocol—record of non-ad-
herence of healthcare professionals to the protocol. These 
reasons will be further explored in the qualitative inter-
views and (5) feasibility of a future definitive RCT—record an 
estimate of the hours per week spent conducting the RCT 
and estimate the number of researchers required and the 
time commitment for healthcare professionals in a future 
RCT.
The qualitative interviews will shed light on contextual 
and other factors that might affect implementation of 
QbTest (both as part of the trial, and within the broader 
processes of care) and will be used to refine the RCT design 
(and QbTest implementation more broadly) if appropriate. 
The qualitative interviews will be transcribed verbatim and 
analysed thematically following the guidelines of Braun 
and Clarke.41 The quantitative and qualitative findings will 
be used to determine the feasibility and acceptability of the 
medication protocol and research study design, and inform 
the decision to proceed to a fully powered RCT.
Monitoring
Management and oversight
Recruitment and study progress will be overseen by our 
project management group (PMG), which includes all 
site principal investigators (JC, KSe, HV), a PPI repre-
sentative (NB), the chief investigator (MJG), the trial 
manager (CLH) and the study team (CH, SB, MJ, BG, 
KSa). The PMG will meet every 6 months, however, any 
severe slippages in recruitment or study milestones will be 
reported to the group immediately by the trial manager 
(CLH). Given this is a feasibility study, a data monitoring 
committee is not necessary.
Adverse events
All adverse events that occur will be assessed for serious-
ness, expectedness and causality. The chief investigator 
(MJG) and the medical expert (CH) shall be informed 
immediately of any serious adverse events and shall deter-
mine seriousness and causality in conjunction with any 
treating medical practitioners. All treatment-related 
serious adverse events will be recorded and reported to 
the Research Ethics Committee (REC). There are no 
anticipated adverse events arising from this study.
Audit
The Trial Coordinator or a nominated designee of the 
Sponsor shall carry out monitoring of trial data as an 
ongoing activity. A sample (10%) of case report forms will 
be checked on a regular basis for verification of all entries 
made. Where corrections are required these will carry a 
full audit trail and justification. Trial data and evidence of 
monitoring and systems audits will be made available for 
inspection by the REC as required.
EthICs And dIssEMInAtIon
 Health Research Authority approvals have been granted 
from the three participating trusts. Only the research team 
will have access to the study data, which will be stored in 
secure locked files or password-protected databases. Data 
will be available for inspection by the ethics committee on 
request. Changes to the protocol will be communicated to 
the ethics committee and trial registries by the trial manager 
(CLH). The process for obtaining participant informed 
consent or assent and parent/guardian/ teacher informed 
consent will be in accordance with the ethical guidance and 
Good Clinical Practice. The investigator or their nominee 
and the participant or other legally authorised representa-
tive (such as the child’s parent) shall both sign and date the 
informed consent forms (online supplementary appendix 
A, B) before the person can participate in the study. Where 
the young person is 16 years and over, written consent will 
be required from the young person and parent alike. Where 
the young person is under 16 years, written parental consent 
will be required, alongside the young person’s written or 
verbal assent. Teachers will also be asked to sign a consent 
form (online supplementary appendix C), if teachers do 
not sign consent the participant is still eligible for the study 
but no teacher measures will be collected. Individual partic-
ipant medical information obtained as a result of this study 
are considered confidential and disclosure to third parties 
is prohibited unless warranted by an adverse event. Partici-
pant confidentiality will be further ensured by using identi-
fication code numbers to correspond to treatment data in 
the computer files. No post-trial care is required.
The findings from the trial will be used to inform 
the design, feasibility and acceptability of a future, 
fully powered RCT. The findings will be published in 
peer-reviewed journals, presented at relevant conferences 
and disseminated to the public via lay summaries co-cre-
ated with our PPI group. All outputs will be authored 
by the research team and will not involve professional 
writers. Access to the full protocol and statistical codes 
are available on request to the corresponding author.
trIAl sponsor
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